Indian drugmaker Mankind Pharma reported a fourth-quarter profit that beat analysts' estimates on Wednesday, driven by strong domestic demand for its drugs to treat long-term illnesses.

The German pharmaceutical company sold it under the brand name Jardiance. Mankind Pharma, India's fourth-largest firm by market share, is selling a generic version of the drug at over one-tenth of ...

July 25 (Reuters) - Indian drugmaker Mankind Pharma (MNKI.NS), opens new tab said late on Thursday it would acquire Bharat Serums and Vaccines Ltd in a deal valued at around 136.30 billion rupees ...

Mankind Pharma has announced a definitive agreement for the acquisition of a 100% stake in Bharat Serums and Vaccines (BSV) from private equity investor Advent International in a Rs136.3bn ($1.6bn ...

Mankind had a 4.4% share of the highly fragmented domestic pharma market as of end-August. Analyst Shah says moving into the top three “is not an impossible goal.” But Mankind faces challenges.

Mankind Pharma Limited on Wednesday announced that it has completed the transaction to acquire 100% stake in Bharat Serums and Vaccines Limited (BSV), for a purchase consideration of Rs.

Motilal Oswal is bullish on Mankind Pharma recommended buy rating on the stock with a target price of Rs 2910 in its research report dated May 22, 2025. Mankind Pharma Consolidated March 2025 Net ...

Mankind Pharma, one of India’s leading pharmaceutical companies, on Monday announced its entry into the topical analgesic market through its consumer business division. According to the company ...

As I step into Rajeev Juneja’s office at Mankind Pharma’s Delhi headquarters, the wall in front of me immediately commands attention. It features a collection of iconic quotes and striking ...

As Mankind Pharma gears up to go public, its 544-page draft IPO paper throws up an interesting name, Dabur India. One wonders why would a century-old fast-moving consumer goods (FMCG) major be ...

Mankind Pharma has clinched the deal to acquire Bharat Serums and Vaccines from private equity firm Advent International for ₹13,630 crore, the company said in a release. The Delhi-based pharma ...